Joint Conference of European Human Pharmacological Societies CLUB PHASE I (France), AGAH (Germany), BAPU (Belgium), AHPPI (UK)

Posted:
28
February 2013

Please join us at theJoint Conference of European Human Pharmacological Societies CLUB PHASE I (France), AGAH (Germany), BAPU (Belgium), AHPPI (UK)11 & 12 April 2013Nice Sophia Antipolis, FranceThe meeting will focus on Early Clinical Utility Assessment of new medicines and how early development should be conducted to optimize the challenging process of reaching efficient and early go/no go decisions.Be part of this European meeting featuring first class plenary sessions and interactive workshops and experience excellent networking opportunities in stimulating surroundings.View programmeRegister online

Please forward this invitation to interested colleagues also.Looking forward to seeing you!Sincerely yoursConference ChairDr. Yves DonazzoloPresident CLUB PHASE IIntercom Kongresse GmbHAntje BlmekeEppendorfer Baum 39a20249 Hamburg (Germany)Phone: +49 40 480610 61Telefax: +49 40 480610 66E-Mail: abloemeke@intercom.deWeb: www.intercom..de

Disclaimer 2013 Intercom Kongresse GmbHEppendorfer Baum 39a, 20249 Hamburg/GermanyUSt-ID DE 1615 400 24, Registry court Hamburg, HRB 113503. All rights reserved. Responsible for contents pursuant to 6 MDStV Managing Director Alexandra Werner.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more